绝经后骨质疏松症患者血清IL-31、IL-33表达变化

doi:10.6040/j.issn.1671-7554.0.2021.0377

摘要/Abstract

摘要： 目的分析白细胞介素-31(IL-31)和白细胞介素-33(IL-33)在绝经后骨质疏松症(PMOP)患者血清中的表达变化,探讨IL-31和IL-33与PMOP的关联性。方法选取绝经后女性共146例,使用双能 X 线骨密度仪(DXA)检测受试者的骨密度,根据骨密度将受试者分为三组:骨量正常组、低骨量组和骨质疏松组。测定血钙(Ca)、磷(P)、甲状旁腺激素(PTH)、25-羟基维生素D(［25( OH)D］)、IL-31、IL-33及骨转换指标血清骨特异性碱性磷酸酶(BALP)、血清1 型原胶原N-端前肽(P1NP)、血清抗酒石酸酸性磷酸酶(TRACP-5b)、血清1型胶原羧基端交联肽(β-CTX)的水平。比较不同骨量的绝经后女性血清IL-31、IL-33及骨转换指标的差异。结果三组受试者的血清IL-31浓度随着骨密度的降低而增加,而血清IL-33浓度随着骨密度的降低而下降,差异均有统计学意义(P<0.05)。多项式 Logistic回归分析结果显示,低骨量组中IL-33(OR:0.987,95%CI:0.974~0.999,P=0.030)差异有统计学意义,骨质疏松组中IL-31(OR:1.019,95%CI:1.009~1.028,P<0.001)、IL-33(OR:0.978,95%CI:0.960~0.995,P=0.013)差异有统计学意义,IL-33的OR值随着骨密度的降低呈下降趋势。提示IL-31和IL-33为PMOP的可能影响因素。结论 IL-31为PMOP的可能危险因素,而IL-33为PMOP的可能保护因素,提示IL-31和IL-33在PMOP 发生过程中起重要作用。

关键词: 绝经后骨质疏松, 白细胞介素-31, 白细胞介素-33, 骨密度, 骨转换指标

Abstract: Objective To analyze the changes of interleukin-31(IL-31)and interleukin-33(IL-33)levels in the serum of postmenopausal osteoporosis(PMOP)patients, and to explore the correlation between PMOP and IL-31/IL-33. Methods A total of 146 postmenopausal women were selected and their bone density was detected with double-energy X-ray absorptiometry(DXA). According to the bone density, the patients were divided into three groups: normal group, low bone mass group and osteoporosis group. Calcium(Ca), phosphorus(P), parathyroid hormone(PTH), 25-hydroxyvitamin D(［25(OH)D］), IL-31, IL-33, bone-specific alkaline phosphatase(BALP), type 1 procollagen N-terminal propeptide(P1NP), anti-tartrate acid phosphatase(TRACP-5b), and β-cross linked C-telopeptide of type 1 collagen(β-CTX)were evaluated. The differences in IL-31, IL-33 and bone turnover markers among the three groups were compared. Results In the three groups, the level of IL-31 showed an upward trend with the decrease of bone density, while the level of IL-33 reduced with the decrease of bone density(P<0.05). Multivariate Logistic regression analysis showed that in the low bone mass group, IL-33(OR: 0.987, 95%CI: 0.974-0.999, P=0.030)was statistically significant, while in the osteoporosis group, IL-31(OR: 1.019, 95%CI: 1.009-1.028, P<0.001)and IL-33(OR: 0.978, 95%CI: 0.960-0.995, P=0.013)were statistically significant. The OR value of IL-33 showed a downward trend with the decrease of bone mineral density, indicating that IL-31 and IL-33 were possible influencing factors of PMOP. Conclusion IL-31 is a possible risk factor for PMOP, while IL-33 is a possible protective factor for PMOP, suggesting that IL-31 and IL-33 play an important role in the pathogenesis of PMOP.

Key words: Postmenopausal osteoporosis, Interleukin-31, Interleukin-33, Bone mineral density, Bone turnover markers

中图分类号:

R574

杜娇娇,庄向华,陈诗鸿,王雪萌,姜冬青,吴菲,韩晓琳,华梦羽,宋玉文. 绝经后骨质疏松症患者血清IL-31、IL-33表达变化[J]. 山东大学学报 (医学版), 2021, 59(6): 45-50.

DU Jiaojiao, ZHUANG Xianghua, CHEN Shihong, WANG Xuemeng, JIANG Dongqing, WU Fei, HAN Xiaolin, HUA Mengyu, SONG Yuwen. Changes of serum IL-31 and IL-33 levels in postmenopausal patients with osteoporosis[J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 45-50.

参考文献

[1] Akkawi I, Zmerly H. Osteoporosis: current concepts [J]. Joints, 2018, 6(2): 122-127.
[2] De Martinis M, Sirufo MM, Ginaldi L. Osteoporosis: current and emerging therapies targeted to immunological checkpoints [J]. Curr Med Chem, 2020, 27(37): 6356-6372.
[3] Ponzetti M, Rucci N. Updates on osteoimmunology: whats new on the cross-talk between bone and immune system [J]. Front Endocrinol(Lausanne), 2019, 10: 236. doi: 10.3389/fendo.2019.00236.
[4] Catalan-Dibene J, Mcintyre LL, Zlotnik A. Interleukin 30 to interleukin 40 [J]. J Interferon Cytokine Res, 2018, 38(10): 423-439.
[5] Ginaldi L, De Martinis M, Ciccarelli F, et al. Increased levels of interleukin 31(IL-31)in osteoporosis [J]. BMC Immunol, 2015, 16: 60. doi: 10.1186/s12865-015-0125-9.
[6] Ginaldi L, De Martinis M, Saitta S, et al. Interleukin-33 serum levels in postmenopausal women with osteoporosis [J]. Sci Rep, 2019, 9(1): 3786.
[7] Petra AI, Tsilioni I, Taracanova A, et al. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E [J]. Allergy Asthma Proc, 2018, 39(2): 153-160.
[8] Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis [J]. Int Immunol, 2010, 22(6): 453-467.
[9] Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [J]. Nat Immunol, 2004, 5(7): 752-760.
[10] Dambacher J, Beigel F, Seiderer J, et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease [J]. Gut, 2007, 56(9): 1257-1265.
[11] Lee CH, Hong CH, Yu WT, et al. Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis [J]. Br J Dermatol, 2012, 167(4): 794-803.
[12] Chattopadhyay S, Tracy E, Liang P, et al. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells [J]. J Biol Chem, 2007, 282(5): 3014-3026.
[13] Takayanagi H. Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption [J]. Nat Rev Rheumatol, 2015, 11(2): 74-76.
[14] 夏维波,章振林,林华,等. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 25(3): 281-309.
[15] Azizieh FY, Shehab D, Al JK, et al. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD [J]. J Inflamm Res, 2019, 12: 99-108. doi: 10.2147/JIR.S203590.
[16] Cop N, Ebo DG, Bridts CH, et al. Influence of IL-6, IL-33, and TNF-alpha on human mast cell activation: Lessons from single cell analysis by flow cytometry [J]. Cytometry B Clin Cytom, 2018, 94(3): 405-411.
[17] Stott B, Lavender P, Lehmann S, et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation [J]. J Allergy Clin Immunol, 2013, 132(2): 446-454.
[18] Schnittker D, Kwofie K, Ashkar A, et al. Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells [J]. Mediators Inflamm, 2013, 2013: 317503. doi: 10.1155/2013/317503.
[19] Rosine N, Etcheto A, Hendel-Chavez H, et al. Increase in Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis [J]. Sci Rep, 2018, 8(1): 7731.
[20] Cornelissen C, Luscher-Firzlaff J, Baron JM, et al. Signaling by IL-31 and functional consequences [J]. Eur J Cell Biol, 2012, 91(6-7): 552-566.
[21] Zhang Q, Putheti P, Zhou Q, et al. Structures and biological functions of IL-31 and IL-31 receptors [J]. Cytokine Growth Factor Rev, 2008, 19(5-6): 347-356.
[22] Perrigoue JG, Li J, Zaph C, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung [J]. J Exp Med, 2007, 204(3): 481-487.
[23] De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity [J]. FEBS Lett, 2005, 579(10): 2035-2039.
[24] Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective [J]. Int J Med Sci, 2012, 9(9): 825-832.
[25] Inada M, Miyaura C. Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis [J]. Clin Calcium, 2010, 20(10): 1467-1472.
[26] Ginaldi L, De Martinis M. Osteoimmunology and Beyond [J]. Curr Med Chem, 2016, 23(33): 3754-3774.
[27] Zoltowska NA, Lei Y, Adner M, et al. Mast cell-dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma [J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(3): 484-492.
[28] Saidi S, Bouri F, Lencel P, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling [J]. Cytokine, 2011, 53(3): 347-354.
[29] Schulze J, Bickert T, Beil FT, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells [J]. J Bone Miner Res, 2011, 26(4): 704-717.
[30] Velickovic M, Pejnovic N, Mitrovic S, et al. ST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in mice [J]. J Endod, 2015, 41(3): 369-375.
[31] Zaiss MM, Kurowska-Stolarska M, Bohm C, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss [J]. J Immunol, 2011, 186(11): 6097-6105.
[32] Taichman RS, Reilly MJ, Matthews LS. Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1alpha in response to interleukin 1beta and tumour necrosis factor alpha stimulation in vitro [J]. Br J Haematol, 2000, 108(2): 275-283.
[33] Da LF, Oliveira AP, Borges D, et al. The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease [J]. Mediators Inflamm, 2014, 2014: 342410. doi: 10.1155/2014/342410.
[34] Saleh H, Eeles D, Hodge JM, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro [J]. Endocrinology, 2011, 152(5): 1911-1922.
[35] Saluja R, Ketelaar ME, Hawro T, et al. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders [J]. Mol Immunol, 2015, 63(1): 80-85.
[36] Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 axis: a potential inflammatory pathway [J]. Mediators Inflamm, 2018, 2018: 3858032. doi: 10.1155/2018/3858032.
[37] Brylka LJ, Schinke T. Chemokines in physiological and pathological bone remodeling [J]. Front Immunol, 2019, 10: 2182. doi: 10.3389/fimmu.2019.02182.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed